Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM) Meeting Abstract

  


Authors: Carvajal, R. D.; Sosman, J. A.; Quevedo, F.; Milhem, M. M.; Joshua, A. M.; Kudchadkar, R. R.; Linette, G. P.; Gajewski, T.; Lutzky, J.; Lawson, D. H.; Lao, C. D.; Flynn, P. J.; Albertini, M. R.; Sato, T.; Paucar, D.; Panageas, K. S.; Dickson, M. A.; Wolchok, J. D.; Chapman, P. B.; Schwartz, G. K.
Abstract Title: Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM)
Meeting Title: 49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 18 Suppl.
Meeting Dates: 2013 May 31-Jun4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-06-20
Language: English
ACCESSION: WOS:000335564000012
PROVIDER: wos
DOI: 10.1200/jco.2013.31.18_suppl.cra9003
Notes: Meeting Abstract: CRA9003 -- Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2013 -- Chicago, IL -- S -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Gary Schwartz
    385 Schwartz
  2. Jedd D Wolchok
    905 Wolchok
  3. Richard D Carvajal
    148 Carvajal
  4. Paul Chapman
    326 Chapman
  5. Katherine S Panageas
    512 Panageas
  6. Mark Andrew Dickson
    170 Dickson
  7. Daniel Paucar
    2 Paucar
Related MSK Work